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Abstract 
Objective 
To compare the effectiveness of prefabricated foot orthoses to rocker-sole footwear in 
reducing foot pain in people with first metatarsophalangeal joint osteoarthritis (1
st
 MTPJ 
OA).   
Design 
Participants (n=102) with 1
st
 MTPJ OA were randomly allocated to receive individualized, 
prefabricated foot orthoses or rocker-sole footwear. The primary outcome measure was the 
pain subscale on the Foot Health Status Questionnaire (FHSQ) at 12 weeks. Secondary 
outcome measures included the function, footwear and general foot health subscales of the 
FHSQ, the Foot Function Index, severity of pain and stiffness at the 1
st
 MTPJ, perception of 
global improvement, general health status, use of rescue medication and co-interventions to 
relieve pain, physical activity and the frequency of self-reported adverse events.   
Results 
The FHSQ pain subscale scores improved in both groups, but no statistically significant 
difference between the groups was observed (adjusted mean difference 2.05 points, 95%CI -
3.61 to 7.71, p=0.477). However, the footwear group exhibited lower adherence (mean [SD] 
total hours worn 287 [193] versus 448 [234], p<0.001), were less likely to report global 
improvement in symptoms (39 versus 62%, relative risk [RR] 0.63, 95% confidence interval 
[CI] 0.41 to 0.99, p=0.043), and were more  likely to experience adverse events (39 versus 
16%, RR 2.47, 95%CI 1.12 to 5.44, p=0.024) compared to the orthoses group. 
Conclusion 
Prefabricated foot orthoses and rocker-sole footwear are similarly effective at reducing foot 
pain in people with 1
st
 MTPJ OA. However, prefabricated foot orthoses may be the 
intervention of choice due to greater adherence and fewer associated adverse events. 
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Trial registration: Australian New Zealand Clinical Trials Registry: 
ACTRN12613001245785. 
Key words: osteoarthritis; foot; footwear; orthoses; biomechanics 
Running title: Orthoses and footwear effectiveness  
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SIGNIFICANCE AND INNOVATIONS 
• This is the first randomized trial to compare the effectiveness of foot orthoses and rocker-
sole shoes in people with 1
st
 MTPJ OA 
• Both interventions were similarly effective at reducing foot pain 
• Adherence was lower and adverse events more common in the rocker-sole footwear 
group 
• Foot orthoses may be the preferred intervention for 1
st
 MTPJ OA   
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Osteoarthritis (OA) of the first metatarsophalangeal joint (1
st
 MTPJ) is the most common 
form of foot OA. Radiographic changes within this joint are observed in up to 35% of people 
aged over 35 years (1), while the population prevalence of symptomatic radiographic 1
st
 
MTPJ OA has recently been estimated as 7.8% in people aged over 50 years (2). The 
condition is characterized by symptoms of joint pain and stiffness, formation of a dorsal 
exostosis, and progressive reduction in range of motion of 1
st
 MTPJ dorsiflexion with 
increasing radiographic severity (3). As a consequence of these changes, 72% of those 
affected report associated locomotor disability (2), and the condition has been shown to have 
a detrimental impact on health-related quality of life (4).  
Several treatments have been proposed for 1
st
 MTPJ OA, including physical therapies, anti-
inflammatory medications, intra-articular injections, foot orthoses, footwear modifications 
and surgery (5). However, the evidence for the effectiveness of these treatments is limited, 
with the most recent systematic review identifying only one very small, low-quality trial of 
two physical therapy programs with a short (four week) follow-up (6). Since the publication 
of this review, one additional trial has been conducted which found that intra-articular 
viscosupplementation with hyaluronan was no more effective than a placebo injection after 
three months of follow-up (7). Clearly, there is a need for additional well-designed trials into 
non-surgical interventions for 1
st
 MTPJ OA.   
Biomechanical factors are thought to contribute to 1
st
 MTPJ OA (8), suggesting that 
mechanical interventions may hold some promise as an effective treatment for this condition. 
One of the most commonly used interventions are foot orthoses, which are thought to 
decrease 1
st
 MTPJ pain by allowing the first metatarsal to plantarflex during the propulsive 
phase of gait, thereby minimising dorsal joint compression (9). A similar effect may also be 
obtained using a footwear modification known as a rocker-sole, which allows the body’s 
centre of mass to ‘roll over’ the base of support, reducing the need for 1
st
 MTPJ dorsiflexion. 
However, evidence to support the effectiveness of foot orthoses for 1
st
 MTPJ OA is limited to 
case reports (10, 11) and one case series study (12). Similarly, the effectiveness of rocker-
sole footwear is largely anecdotal, with only one small case series suggesting that rocker-sole 
footwear was effective when combined with intra-articular corticosteroid injection (13).      
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Given the prevalence and impact of 1
st
 MTPJ OA and the lack of evidence for existing 
interventions, the objective of this study was to compare the effectiveness of prefabricated 
foot orthoses to rocker-sole footwear in reducing foot pain in people with 1
st
 MTPJ OA.  
METHODS 
Trial design 
The trial was prospectively registered with the Australian New Zealand Clinical Trials 
Registry (ACTRN12613001245785). The La Trobe University Human Ethics Committee 
provided ethical approval (number 13-003) and all participants provided written informed 
consent prior to enrolment. The full trial protocol has been published previously (14). The 
study design was a parallel-group randomized trial comparing two interventions: 
prefabricated foot orthoses versus commercially available rocker-sole footwear (MBT

, 
Masai Barefoot Technology, Switzerland). Participants were informed that they would 
receive either the foot orthoses or rocker-sole footwear (i.e. they were not blinded to their 
group allocation). Due to the nature of the intervention, research staff administering the 
treatments were not blinded to group allocation. However, follow-up assessment of outcome 
measures was via self-completion questionnaires returned by mail, and staff entering outcome 
measure data and conducting statistical analyses were blinded. 
Participants 
Between February and October 2014 we recruited participants via (i) radio advertisements, 
(ii) advertisements placed in local newspapers, magazines, and social media, (iii) posters 
placed at healthcare facilities, gymnasiums, senior citizens’ centres, fun runs and markets, 
and (iv) mail-out advertisements to patients attending the La Trobe University Health 
Sciences clinic and to local podiatry clinics.  
To be included in the study, participants had to (i) be aged at least 18 years, (ii) report having 
pain in the 1
st
 MTPJ on most days for at least 12 weeks, (iii) report having pain rated at least 
20 mm on a 100 mm visual analogue scale (VAS), (iv) have less than 64 degrees of 
dorsiflexion range of motion of the 1
st
 MTPJ (15), (v) have pain upon palpation of the dorsal 
aspect of the 1
st
 MTPJ, (vi) be able to walk household distances (>50 metres) without the aid 
of a walker, crutches or cane, (vii) be willing to attend the Health Sciences Clinic at La Trobe 
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University (Melbourne, Victoria, Australia) on two occasions and have their foot x-rayed, 
(viii) be willing to not receive additional interventions (such as physical therapy, foot 
orthoses, shoe modifications, intra-articular injections, or surgery) for the 1
st
 MTPJ pain 
during the course of the study, and (ix) be willing to discontinue taking all medications to 
relieve pain at their 1
st
 MTPJ (analgesics and non-steroidal anti-inflammatory medications 
[NSAIDs], except paracetamol up to 4 g/day) for at least 14 days prior to the baseline 
assessment and during the study period.  
Exclusion criteria included (i) pregnancy, (ii) previous surgery on the 1
st
 MTPJ, (iii) 
significant deformity of the 1
st
 MTPJ including hallux valgus (grade of 3 or 4 scored using 
the Manchester Scale) (16, 17), (iv) presence of one or more conditions within the foot or 
ankle, which, in the opinion of the investigators, could confound pain and functional 
assessments of the 1
st
 MTPJ, such as metatarsalgia, plantar fasciitis, pre-dislocation 
syndrome, Achilles tendinopathy or degenerative joint disease (other than the 1
st
 MTPJ), 
determined by a podiatrist, (v) presence of any systemic inflammatory condition, such as 
inflammatory arthritis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, 
reactive arthritis, septic arthritis, acute pseudogout, gout or any other connective tissue 
disease, (vi) any medical condition that, in the opinion of the investigators, made the 
participant unsuitable for inclusion (e.g., severe progressive chronic disease, malignancy, 
clinically important pain in a part of the musculoskeletal system other than the 1
st
 MTPJ, or 
fibromyalgia), (vii) cognitive impairment (defined as a score of <7 on the Short Portable 
Mental Status Questionnaire) (18), (viii) intra-articular injections into the 1
st
 MTPJ in the 
previous 6 months, (ix) currently wearing contoured foot orthoses (although flat insoles were 
permitted), (x) currently wearing specialized footwear (footwear that has been custom-made 
or ‘prescribed’ by a health-care practitioner), (xi) currently wearing shoes that would not be 
able to accommodate a foot orthosis, or (xii) older people with a history of recurrent falls 
(defined as two or more falls in the previous 12 months), as there is some evidence that 
rocker-sole shoes may have short-term detrimental effects on balance (19). 
Randomization 
Permuted block randomization with random block sizes, stratified by sex, was undertaken 
using an interactive voice response telephone service provided by the NHMRC Clinical 
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Trials Centre at the University of Sydney, New South Wales, Australia to ensure allocation 
concealment (14). 
Clinical and radiographic assessment 
All assessments and interventions were performed at the La Trobe University Health 
Sciences Clinic, Melbourne, Victoria, Australia. At baseline, participants underwent a clinical 
assessment including measurements of height, weight and body mass index (BMI), foot 
posture (using the Foot Posture Index (20)), passive non-weightbearing dorsiflexion range of 
motion at the 1
st
 MTPJ (21) and observation to determine the presence or absence of pain on 
palpation, a dorsal exostosis, joint effusion, pain during motion, a hard-end feel when the 
joint was fully dorsiflexed, and crepitus during movement. The reliability of these 
assessments has previously been documented (15). 
The presence of radiographic 1
st
 MTPJ OA was determined at baseline using a radiographic 
atlas developed by Menz et al. (22). The atlas incorporates weightbearing dorso-plantar and 
lateral radiographs to document the presence of OA based on observations of osteophytes and 
joint space narrowing. Osteophytes were recorded as absent (score = 0), small (score = 1), 
moderate (score = 2) or severe (score = 3). Joint space narrowing was recorded as none (score 
= 0), definite (score = 1), severe (score = 2) or joint fusion (score = 3). Radiographic OA 
using this atlas is defined as a score of 2 or more for osteophytes or joint space narrowing on 
either dorso-plantar and lateral views. The atlas has been shown to have good to excellent 
intra- and inter-rater reliability for grading 1
st
 MTPJ OA (ĸ range 0.64 to 0.95) (22).        
Interventions 
The prefabricated foot orthoses group received a pair of foot orthoses (Vasyli Customs 
Medium Density, Vasyli Medical™, Queensland, Australia) that were modified using a 
similar approach to that described by Welsh et al. (12) All orthoses were full-length, but were 
modified by adding a cut-out section beneath the first metatarsal and trimming the distal edge 
to the level of the second to fifth toe sulci (Figure 1). In participants with pronated feet 
(defined as a Foot Posture Index [FPI] score of >7 (23)), full length, four-degree medial 
(varus) wedges were applied to the underside of the foot orthoses until there was a reduction 
in the FPI score of at least two points (12). The wedge was gradually bevelled so that it 
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extended to the proximal margin of the cut-out section beneath the first metatarsal.  The 
rocker-sole footwear group were provided with a pair of rocker-sole shoes (MBT

 
Mahuta/Matwa, Masai Barefoot Technology, Switzerland). These shoes are characterized by 
a rounded sole in the antero-posterior direction and a soft cushioned heel (Figure 2). Across 
the full size range, the radius of curvature of the MBT is on average 33 cm overall, 18 cm at 
the forefoot, 43 cm at the midfoot, and 11 cm at the heel (24). Fitting of the shoes was 
undertaken by trained assessors using the Brannock Device
®
. All participants received an 
information handout which outlined the appropriate use and care of their orthoses or 
footwear.   
Outcome measures 
The primary outcome measure was the foot pain domain of the Foot Health Status 
Questionnaire (FHSQ) (25), measured at baseline, 4, 8 and 12 weeks. The FHSQ is a foot-
specific health-related quality of life outcome measure consisting of 13 questions that assess 
four domains of foot health including pain, function, footwear and general foot health. 
Questions within each domain are scored using a Likert response format, with an output score 
produced ranging from 0 to 100, with a score of 100 indicating optimum foot health and a 
score of 0 indicating very poor foot health. The FHSQ has been shown to have a high degree 
of internal consistency (Cronbach's α=0.88) and test-retest reliability (intra-class correlation 
coefficient=0.86 (25)), and is a widely recommended outcome measure in clinical trials of 
rheumatological foot disorders (26). Participants treated for bilateral symptoms were asked to 
describe symptoms of their most painful foot. If both feet were equally painful, the right foot 
was selected as the index foot.  
Secondary outcome measures included: (i) the function domain of the FHSQ, measured at 
baseline, 4, 8 and 12 weeks, (ii) the Foot Function Index - Revised (Short Form) (27), 
measured at baseline and 12 weeks, (iii) severity of pain at the 1
st
 MTPJ while walking over a 
flat surface and during rest over the last week (each via a 100 mm visual analog scale 
[VAS]), measured at baseline, 4, 8 and 12 weeks, (iv) duration and severity of stiffness at the 
1
st
 MTPJ after first awakening in the morning, during the last week (via a 100 mm VAS), 
measured at baseline, 4, 8 and 12 weeks, (v) severity of stiffness after sitting, lying, or resting 
later in the day, during the last week (via a 100 mm VAS), measured at baseline, 4, 8 and 12 
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weeks, (vi) global change in symptoms using a 15-point Likert scale (7=a very great deal 
better, 6=a great deal better, 5=a good deal better, 4=moderately better, 3=somewhat better, 
2=a little better, 1=about the same, hardly any better at all, 0=no change, -1=about the same, 
hardly any worse at all, -2=a little worse, -3=somewhat worse, -4=moderately worse, -5=a 
good deal worse, -6=a great deal worse, -7=a very great deal worse, with a dichotomised 
score of ≥ 4 representing improvement), measured at 12 weeks, (vii) health status (using the 
Short-Form-12 Version 2 questionnaire) (28), measured at baseline and 12 weeks, (viii) use 
of paracetamol rescue medication (number of participants and mean consumption) and co-
interventions to relieve pain at the 1
st
 MTPJ, documented with a monthly diary throughout 
the 12 week study period, (ix) the frequency and type of self-reported adverse events (defined 
as an unwanted event that may or may not be related to the treatment) collected at 4 weekly 
intervals throughout the 12 week study period, and (x) the Incidental and Planned Activity 
Questionnaire, a self-report questionnaire that covers the frequency and duration of several 
levels of planned and incidental physical activity (29), measured at baseline and 12 weeks.  
To maximize response to the postal questionnaire outcome measures, we sent emails or 
letters after one week to non-responders, and then followed-up with up to three attempted 
contacts by telephone and/or email over a two week period. 
Sample size 
The sample size for the study was determined using an a priori power analysis based on the 
primary outcome measure: the pain domain of the Foot Health Status Questionnaire (FHSQ) 
(25). We have previously determined that the minimal important difference for this measure 
in people with foot pain is 13 points (30). Using a standard deviation of 19 (derived from our 
recent trial (7)), a power level of 0.8, alpha level of 0.05 and accounting for a drop-out rate of 
15%, we determined that a sample size of 80 participants (i.e. approximately 40 per group) 
was required. 
Statistical analysis 
Statistical analysis was undertaken using SPSS version 22.0 (IBM Corp, NY, USA) using the 
intention-to-treat principle for all randomized participants (31). Multiple imputation was used 
to replace missing data using five iterations, with age, baseline scores, and group allocation 
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as predictors (32). The exception was the use of co-interventions, rescue medication and 
adverse events, where no data substitution was applied. Continuously-scored outcome 
measures were analysed using analysis of covariance (ANCOVA) with baseline scores and 
intervention group entered as independent variables (33). Dichotomously-scored outcome 
measures were compared using relative risk, and number needed to treat/harm (NNT/NNH). 
To avoid over-testing and to minimize the risk of Type I error associated with serial 
measurements, statistical analysis of the effectiveness of the interventions specifically 
focused on the change in outcome measures between baseline and 12 weeks (34, 35). 
RESULTS 
Participant characteristics 
Figure 3 shows the flow of participants through the study. The sample consisted of 102 
participants (45 men and 57 women) aged 22 to 78 years (mean 56.8, SD 11.1). Fifty-two 
participants were allocated to the orthoses group and 50 to the footwear group. Participants in 
the two groups had similar baseline characteristics (Table 1). Four participants in the 
footwear group withdrew consent after randomization and did not receive their allocated 
intervention. Of these, two could not tolerate the shoes, one had very large feet that could not 
be accommodated in the available size range, and one withdrew on advice from their 
chiropractor. Shortly after commencing the study, the MBT

 shoe we used (the ‘Mahuta’ 
model) was discontinued by the company and replaced with the ‘Matwa’ model, resulting in 
four participants receiving the Mahuta and 42 receiving the Matwa. However, both models 
had the same sole curvature and only differed slightly in relation to the aesthetics of the 
upper. Two participants in the orthoses group had pronated feet (FPI>7), so had varus 
wedged applied to their orthoses according to the pre-specified protocol (14).        
Participant retention and intervention adherence 
By the 12 week follow-up, there were five drop-outs in the orthoses group (one withdrew as 
they could not tolerate the orthoses, and four were lost to follow-up) and five drop-outs in the 
footwear group (two withdrew as they could not tolerate the footwear, and three lost to 
follow-up), giving completion rates of 90 and 89%, respectively. Participants in the orthoses 
group reported wearing their intervention for a greater number of hours than the footwear 
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group (mean [SD] total hours worn over study period = 448 [238] versus 287 [192]; 
p<0.001).  
Primary outcome 
Table 2 shows the mean (SD) scores and adjusted mean differences (95% CIs) between 
groups for the FHSQ pain domain at baseline and at 4, 8 and 12 weeks follow-up. Both 
groups demonstrated an increase in the FHSQ pain domain score (17 points in the orthoses 
group and 22 points in the footwear group), which is indicative of improved foot health. 
However, there was no difference between the groups at the 12 week follow-up (ANCOVA 
adjusted mean difference of 2.05 points, 95% CI -3.61 to 7.71, p=0.477).  
Secondary outcomes 
Table 2 shows the mean (SD) scores and adjusted mean differences (95% CIs) between 
groups for the secondary outcome measures (FHSQ function domain, FFI, pain and stiffness, 
SF-12 and physical activity levels). There were no differences between the groups at the 12 
week follow-up for any of these measures. However, at the completion of the study, the 
perception of global improvement, defined as at least moderate improvement (score ≥ 4) on 
the 15-point Likert scale, was lower in the footwear group (39 versus 62%, RR 0.63, 95% CI 
0.41 to 0.99, p=0.043). The NNH was 5 (95% CI 2.3 to 43.9), meaning that one in every five 
participants treated with footwear had an unsuccessful outcome compared to those receiving 
orthoses.  
Use of cointerventions 
There was no difference in the proportion of participants reporting use of cointerventions 
between the orthoses and footwear groups (18 versus 15%; RR 0.87, 95% CI 0.33 to 2.28, 
p=0.770) and no difference in the proportion of participants who reported consuming rescue 
medications between the orthoses and footwear groups (24 versus 28%, RR1.15, 95%CI 0.56 
to 2.36, p=0.696).   
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Adverse events 
Adverse events are reported in Table 3. The most commonly reported adverse events were 
new episodes of back or lower limb pain (n=44), blisters (n=5), discomfort associated with 
the intervention (n=5) and impaired balance (n=5). Participants in the footwear group were 
more likely to report at least one adverse event (39 versus 16%, RR 2.47, 95% CI 1.12 to 
5.44, p=0.024; NNH 5, 95% CI 2.4 to 23.1) and were more likely to report a new episode of 
low back pain during the study than the orthoses group (17 versus 4%, RR 4.52, 95% CI 1.01 
to 20.22, p=0.048; NNH 10, 95% CI 4.6 to 677.9).  
DISCUSSION  
This is the first randomized trial to evaluate the effectiveness of mechanical interventions in 
reducing foot pain in people with first metatarsophalangeal joint osteoarthritis (1
st
 MTPJ 
OA). We found that both the orthoses and footwear groups demonstrated an increase in the 
Foot Health Status Questionnaire (FHSQ) pain domain score (indicative of an improvement 
in foot health), but there was no difference between the groups at the 12 week follow-up. 
However, the footwear group reported lower adherence, were less likely to report at least 
moderate improvement in symptoms, and were more likely to experience adverse events, 
particularly new onset low back pain, compared to the orthoses group. Taken together, these 
findings suggest that prefabricated foot orthoses may be the preferred intervention in the 
treatment of 1
st
 MTPJ OA.  
The primary outcome measure (FHSQ pain domain) increased in both groups at the 12 week 
follow-up: by 17 points in the orthoses group and 22 points in the footwear group. This 
change in FHSQ scores exceeds the minimal important difference for this measure (13 
points) (30). However, because this is not a controlled trial, we cannot be certain of the extent 
to which the observed changes are true therapeutic effects as opposed to placebo effects, 
Hawthorne effects, regression to the mean, or natural resolution. We originally intended to 
provide sham orthoses (36) as the comparator to the rocker-sole footwear, however this was 
considered by our ethics committee to be withholding usual care and was not permitted (14). 
Nevertheless, our analysis of the biomechanical effects of these interventions at the baseline 
appointment indicated that both interventions were similarly effective at reducing peak 
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pressure under the 1
st
 MTPJ compared to participants’ usual footwear (37), which may at 
least partly explain the similar improvement in symptoms we observed at follow-up. 
Adherence varied markedly between the two groups. We found that the footwear group wore 
their shoes for an average of 287 hours in total throughout the 12 week study period, 
compared to 448 hours for the orthoses group. This finding was not unexpected, as due to the 
pronounced sole curvature, the MBT

 shoes have a characteristic appearance which may not 
have been aesthetically acceptable to all participants. Furthermore, because many of our 
participants were of working age, workplace attire constraints may have created a barrier to 
wearing the allocated footwear. Low adherence is a well-recognized problem with footwear 
intervention studies and has been attributed to the unique role of footwear as both an item of 
clothing and a health-related intervention (38). In contrast, the orthoses are transferrable, can 
be accommodated in most types of footwear, and are hidden from view, which may have 
facilitated them being worn more frequently. These observations suggest that orthoses may 
be a more practical intervention. However, given that the change in FHSQ pain scores was 
similar between the groups despite marked differences in adherence, it is possible that the 
rocker-sole shoes have the potential for greater effectiveness if barriers to adherence could be 
overcome.   
Adverse events were more common in the footwear group. Most of these were relatively 
minor (such as blisters and general discomfort), however the increased risk of new onset low 
back pain is a notable finding. We cannot be certain that the footwear caused the low back 
pain reported by these participants, nor whether these cases were merely transient episodes 
reflecting a habituation period associated with wearing the shoes. Nevertheless, 
biomechanical studies have reported increased thoracic motion and lumbar erector spinae 
muscle activity when standing (39) and a trend towards increased activity of gluteus medius 
when walking (40) when wearing MBT

 shoes. These changes have generally been 
interpreted as potentially beneficial for people with low back pain, as they are thought to 
represent a ‘training’ effect on pelvic and spinal muscles responsible for postural control (41). 
However, evidence pertaining to the effectiveness of MBT

 shoes in the treatment of low 
back pain is equivocal (42, 43). It is also possible that such changes may be detrimental to 
those who do not have low back pain, and may explain the higher rate of new onset low back 
pain we observed in the footwear group. 
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Key strengths of this study include the use of well-validated outcome measures, high 
participant retention and broad generalizability. However, our findings need to be interpreted 
in the context of several methodological limitations. Firstly, as previously discussed, this was 
not a controlled trial, so we cannot be certain that the observed changes in participant-
reported outcome measures are true therapeutic effects. Secondly, it was not possible to blind 
participants to their intervention. Thirdly, not all participants met the case definition for 
radiographic OA described by Menz et al. (22), which requires a score of 2 or more for 
osteophytes or joint space narrowing on either dorso-plantar and lateral views. In order to 
minimize costs and radiation exposure, we did not use radiographs for eligibility screening, 
and instead used the clinical diagnostic tests described by Zammit et al. (15) to identify 
participants with likely OA. In our sample, this clinical model was sensitive but not specific, 
meaning that 28 participants included in the trial did not meet the Menz et al. (22) case 
definition. Nevertheless, these participants all showed at least some radiographic changes and 
exhibited other cardinal signs of 1
st
 MTPJ OA. Finally, we used a specific model of MBT

 
shoe and prefabricated orthosis, so it is unclear whether our findings can be generalized to 
other types of rocker-sole shoes or orthoses which may have different biomechanical effects.   
In summary, this randomized trial has shown that prefabricated foot orthoses and rocker-sole 
footwear are similarly effective at reducing foot pain in people with 1
st
 MTPJ OA. However, 
the higher adherence and lower rate of adverse events we observed in the orthoses group 
suggests that prefabricated foot orthoses may be the preferred intervention for this condition. 
Future research should focus on examining the effectiveness of other types of orthoses and 
footwear interventions compared to a sham intervention, identifying who is most likely to 
benefit from mechanical interventions, and determining whether barriers to adherence with 
rocker-sole footwear can be overcome by addressing concerns related to aesthetics and 
comfort.          
COMPETING INTERESTS 
The authors declare that they have no competing interests. 
AUTHORS' CONTRIBUTIONS 
HBM, SEM and PL conceived the idea and obtained funding for the study. HBM, SEM and 
Page 15 of 31
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
16 
 
PL designed the trial protocol with input from JMT, MA and ER. HBM drafted the 
manuscript with input from SEM, PL, JMT, MA and ER. All authors have read and approved 
the final manuscript. 
ACKNOWLEDGEMENTS  
This study was funded by the National Health and Medical Research Council (ID: 1049085). 
HBM is currently a National Health and Medical Research Council Senior Research Fellow 
(ID: 1020925). We would like to thank Gary Yodgee (Yodgee Footwear) for providing the 
footwear used in the study at reduced cost, Matt Barkley and Craig Truscott (Vasyli Medical) 
for providing the prefabricated foot orthoses used in the study at reduced cost, and Southern 
Cross Medical Imaging for conducting the x-rays at reduced cost.  
Page 16 of 31
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
17 
 
REFERENCES 
1. Trivedi B, Marshall M, Belcher J, Roddy E. A systematic review of radiographic 
definitions of foot osteoarthritis in population-based studies. Osteoarthritis Cartilage. 
2010;18:1027-35. 
2. Roddy E, Thomas MJ, Marshall M, Rathod T, Myers H, Menz HB, et al. The population 
prevalence of symptomatic radiographic foot osteoarthritis in community-dwelling older 
adults: the Clinical Assessment Study of the Foot. Ann Rheum Dis. 2015;74:156-63. 
3. Menz HB, Roddy E, Marshall M, Thomas MJ, Rathod T, Myers H, et al. Demographic and 
clinical factors associated with radiographic severity of first metatarsophalangeal joint 
osteoarthritis: cross-sectional findings from the Clinical Assessment Study of the Foot. 
Osteoarthritis Cartilage. 2015;23(1):77-82. 
4. Bergin SM, Munteanu SE, Zammit GV, Nikolopoulos N, Menz HB. Impact of first 
metatarsophalangeal joint osteoarthritis on health-related quality of life. Arthritis Care Res. 
2012;64(11):1691-8. 
5. Vanore JV, Christensen JC, Kravitz SR, Schuberth JM, Thomas JL, Weil LS, et al. 
Diagnosis and treatment of first metatarsophalangeal joint disorders. Section 2: Hallux 
Rigidus. J Foot Ankle Surg. 2003;42:124-36. 
6. Zammit GV, Menz HB, Munteanu SE, Landorf KB, Gilheany MF. Interventions for 
treating osteoarthritis of the big toe joint. Cochrane Database Syst Rev. 2010(9):CD007809. 
7. Munteanu SE, Zammit GV, Menz HB, Landorf KB, Handley CJ, Elzarka A, et al. 
Effectiveness of intra-articular hyaluronan (Synvisc, hylan G-F 20) for the treatment of first 
metatarsophalangeal joint osteoarthritis: a randomised placebo-controlled trial. Ann Rheum 
Dis. 2011;70:1838-41. 
8. Zammit GV, Menz HB, Munteanu SE. Structural factors associated with hallux 
limitus/rigidus: a systematic review of case control studies. J Orthop Sports Phys Ther. 
2009;39(10):733-42. 
Page 17 of 31
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
18 
 
9. Rosenbloom KB. Pathology-designed custom molded foot orthoses. Clin Podiatr Med 
Surg. 2011;28:171-87. 
10. Michaud TC. Pathomechanics and treatment of hallux limitus: A case report. Chiropr 
Sport Med. 1988;2:55-60. 
11. Michaud TC, Nawoczenski DA. The influence of two different types of foot orthoses on 
first metatarsophalangeal joint kinematics during gait in a single subject. J Manipulative 
Physiol Ther. 2006;29:60-5. 
12. Welsh BJ, Redmond AC, Chockalingam N, Keenan AM. A case-series study to explore 
the efficacy of foot orthoses in treating first metatarsophalangeal joint pain. J Foot Ankle Res. 
2010;3:17. 
13. Trepman E, Yeo S. Non-operative treatment of metatarsophalangeal joint synovitis. Foot 
Ankle Int. 1995;16:771-7. 
14. Menz HB, Levinger P, Tan JM, Auhl M, Roddy E, Munteanu SE. Rocker-sole footwear 
versus prefabricated foot orthoses for the treatment of pain associated with first 
metatarsophalangeal joint osteoarthritis: study protocol for a randomised trial. BMC 
Musculoskelet Disord. 2014;15:86. 
15. Zammit GV, Munteanu SE, Menz HB. Development of a diagnostic rule for identifying 
radiographic osteoarthritis in people with first metatarsophalangeal joint pain. Osteoarthritis 
Cartilage. 2011;19(8):939-45. 
16. Garrow AP, Papageorgiou A, Silman AJ, Thomas E, Jayson MI, Macfarlane GJ. The 
grading of hallux valgus. The Manchester Scale. J Am Podiatr Med Assoc. 2001;91:74-8. 
17. Menz HB, Munteanu SE. Radiographic validation of the Manchester scale for the 
classification of hallux valgus deformity. Rheumatology. 2005;44:1061-6. 
18. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic 
brain deficit in elderly patients. J Am Geriatr Soc. 1975;23:433-41. 
Page 18 of 31
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
19 
 
19. Albright BC, Woodhull-Smith WM. Rocker bottom soles alter the postural response to 
backward translation during stance. Gait Posture. 2009;30(1):45-9. 
20. Redmond AC, Crosbie J, Ouvrier RA. Development and validation of a novel rating 
system for scoring standing foot posture: The Foot Posture Index. Clin Biomech. 2006;21:89-
98. 
21. Buell T, Green DR, Risser J. Measurement of the first metatarsophalangeal joint range of 
motion. J Am Podiatr Med Assoc. 1988;78:439-48. 
22. Menz HB, Munteanu SE, Landorf KB, Zammit GV, Cicuttini FM. Radiographic 
classification of osteoarthritis in commonly affected joints of the foot. Osteoarthritis 
Cartilage. 2007;15:1333-8. 
23. Redmond AC, Crane YZ, Menz HB. Normative values for the Foot Posture Index. J Foot 
Ankle Res. 2008;1:6. 
24. Forghany S, Nester CJ, Richards B. The effect of rollover footwear on the rollover 
function of walking. J Foot Ankle Res. 2013;6:24. 
25. Bennett P, Patterson C, Wearing S, Baglioni T. Development and validation of a 
questionnaire designed to measure foot-health status. J Am Podiatr Med Assoc. 1998;88:419-
28. 
26. Riskowski JL, Hagedorn TJ, Hannan MT. Measures of foot function, foot health, and foot 
pain: American Academy of Orthopedic Surgeons Lower Limb Outcomes Assessment: Foot 
and Ankle Module (AAOS-FAM), Bristol Foot Score (BFS), Revised Foot Function Index 
(FFI-R), Foot Health Status Questionnaire (FHSQ), Manchester Foot Pain and Disability 
Index (MFPDI), Podiatric Health Questionnaire (PHQ), and Rowan Foot Pain Assessment 
(ROFPAQ). Arthritis Care Res. 2011;63 Suppl 11:S229-39. 
27. Budiman-Mak E, Conrad KJ, Mazza J, Stuck RM. A review of the foot function index 
and the foot function index – revised. J Foot Ankle Res. 2013;6:5. 
28. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of 
scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-33. 
Page 19 of 31
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
20 
 
29. Delbaere K, Hauer K, Lord SR. Evaluation of the incidental and planned activity 
questionnaire for older people. Br J Sports Med. 2010;44:1029-34. 
30. Landorf KB, Radford JA, Hudson S. Minimal Important Difference (MID) of two 
commonly used outcome measures for foot problems. J Foot Ankle Res. 2010;3:7. 
31. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for 
reporting parallel group randomised trials. BMJ. 2010;340:c332. 
32. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple 
imputation for missing data in epidemiological and clinical research: potential and pitfalls. 
BMJ. 2009;338:b2393. 
33. Vickers AJ, Altman DG. Statistics notes: Analysing controlled trials with baseline and 
follow up measurements. BMJ. 2001;323:1123-4. 
34. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in 
medical research. BMJ. 1990;300:230-5. 
35. Bender R, Lange S. Adjusting for multiple testing--when and how? J Clin Epidemiol. 
2001;54:343-9. 
36. McCormick C, Bonanno DB, Landorf KB. The effect of customised and sham foot 
orthoses on plantar pressures. J Foot Ankle Res. 2013;6:19. 
37. Menz HB, Auhl M, Tan JM, Levinger P, Roddy E, Munteanu SE. Biomechanical effects 
of prefabricated foot orthoses and rocker-sole footwear in individuals with first 
metatarsophalangeal joint osteoarthritis. Arthritis Care Res. 2015 (accepted manuscript). 
38. Williams AE, Nester CJ, Ravey MI, Kottink A, Klapsing MG. Women's experiences of 
wearing therapeutic footwear in three European countries. J Foot Ankle Res. 2010;3:23. 
39. Buchecker M, Stoggl T, Muller E. Spine kinematics and trunk muscle activity during 
bipedal standing using unstable footwear. Scand J Med Sci Sports. 2013;23(3):e194-201. 
40. Nigg B, Hintzen S, Ferber R. Effect of an unstable shoe construction on lower extremity 
gait characteristics. Clin Biomech. 2006;21:82-8. 
Page 20 of 31
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
21 
 
41. Nigg B, Federolf PA, vonTscharner V, Nigg S. Unstable shoes: functional concepts and 
scientific evidence. Footwear Sci. 2012;4:73-82. 
42. Nigg BM, Davis E, Lindsay D, Emery C. The effectiveness of an unstable sandal on low 
back pain and golf performance. Clin J Sport Med. 2009;19(6):464-70. 
43. MacRae CS, Lewis JS, Shortland AP, Morrissey MC, Critchley D. Effectiveness of 
rocker sole shoes in the management of chronic low back pain: a randomized clinical trial. 
Spine. 2013;38(22):1905-12.  
Page 21 of 31
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
22 
 
 Table 1. Participant characteristics at baseline. Values are mean (SD) unless otherwise 
noted. 
 
 Orthoses group (n=52) Footwear group (n=46) 
Demographics and anthropometrics   
Age – years 57.1 (11.1) 56.5 (11.1) 
Female – n (%) 29 (55.8) 28 (60.9) 
Height – cm 166.0 (8.90) 166.3 (8.3) 
Weight – kg 80.5 (14.9) 78.5 (13.3) 
Body mass index – kg/m2 29.2 (4.8) 28.4 (4.5) 
General health   
SF-12 – physical 44.1 (10.7) 45.0 (9.7) 
SF-12 – mental 55.8 (8.1) 51.9 (9.0) 
Toal physical activity – hours / week 17.5 (14.6) 15.4 (11.4) 
Clinical features   
Pain duration – months, median (range) 33 (4 to 360) 30 (6 to 420) 
Foot Posture Index – mean (SD) [range] 3.0 (2.4) [-2 to 11] 3.4 (2.2) [-2 to 10] 
1st MTPJ ROM – degrees 39.8 (12.5) 40.5 (13.0) 
Pain on palpation – n (%) 52 (100) 46 (100) 
Palpable dorsal exostosis – n (%) 50 (96.2) 45 (97.8) 
Joint effusion – n (%)  17 (33.3) 16 (34.8) 
Pain on motion of 1st MTPJ – n (%) 49 (94.2) 41 (91.1) 
Hard-end feel when dorsiflexed – n (%) 47 (90.4) 39 (84.8) 
Crepitus – n (%) 35 (67.3) 30 (65.2) 
Radiographic features – n (%)*   
Dorsal osteophytes 50 (96.2) 39 (84.8) 
Dorsal joint space narrowing 43 (82.7) 39 (84.8) 
Lateral osteophytes 42 (80.8) 39 (84.8) 
Lateral joint space narrowing 45 (86.5) 38 (82.6) 
Radiographic 1
st
 MTPJ OA† 37 (71.2) 33 (76.7) 
SF-12=Short Form 12 Health Survey; MTPJ=metatarsophalangeal joint; ROM=range of motion; OA=osteoarthritis 
* score >0 using Menz et al. atlas 
† at least one score of 2 for osteophytes or joint space narrowing from either view, using case definition from Menz et al. 
atlas 
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Table 2. Primary and secondary outcome measures at baseline and follow-up. Values are 
mean (SD). 
 
 Orthoses group 
(n=52) 
Footwear group 
(n=46) 
Adjusted mean difference 
(95% CI)* 
p 
FHSQ – pain domain (0-100 
points)† 
    
Baseline 56.7 (19.2) 51.5 (20.3)   
4 weeks 68.4 (15.8) 64.5 (17.5)   
8 weeks 73.2 (15.6) 67.9 (17.9)   
12 weeks 73.6 (16.8) 73.7 (14.80) 2.05 (-3.61 to 7.71) 0.477 
FHSQ – function domain (0-100 
points)† 
    
Baseline 70.8 (22.0) 67.4 (25.5)   
4 weeks 79.0 (20.8) 76.9 (20.9)   
8 weeks 81.5 (18.1) 77.4 (17.3)   
12 weeks 82.7 (18.6) 80.5 (16.6) -0.24 (-4.95 to 4.47) 0.920 
FFI – pain (0-100 points)†     
Baseline 40.5 (17.0) 41.9 (18.7)   
12 weeks 42.4 (12.7) 41.0 (12.5) -1.80 (-6.14 to 2.55) 0.418 
FFI – stiffness (0-100 points)†     
Baseline 33.4 (19.5) 37.1 (23.4)   
12 weeks 41.1 (13.0) 42.0 (16.3) -0.25 (-5.59 to 5.08) 0.926 
FFI – difficulty (0-100 points)†     
Baseline 37.6 (24.5) 40.0 (25.0)   
12 weeks 43.7 (14.8) 46.3 (16.0) 1.69 (-3.11 to 6.49) 0.489 
FFI – overall (0-100 points)†     
Baseline 37.0 (18.8) 39.6 (20.7)   
12 weeks 42.5 (11.3) 43.1 (13.8) -0.39 (-4.14 to 3.37) 0.840 
Pain severity while walking (0-
100mm)‡  
    
Baseline 46.4 (21.9) 47.5 (22.4)   
4 weeks 27.0 (20.6) 30.1 (21.9)   
8 weeks 24.6 (19.9) 24.8 (18.6)   
12 weeks 23.0 (20.7) 20.3 (16.0) -2.89 (-10.40 to 4.61) 0.450 
Pain severity at rest (0-100mm)‡     
Baseline 32.4 (24.8) 34.4 (25.4)   
4 weeks 20.5 (18.7) 21.7 (20.0)   
8 weeks 15.8 (16.7) 17.8 (18.5)   
12 weeks 17.0 (19.6) 16.4 (19.2) -1.27 (-8.31 to 5.78) 0.724 
Stiffness severity in morning (0-
100mm)‡ 
    
Baseline 32.1 (26.3) 39.3 (25.2)   
4 weeks 19.5 (15.9) 26.4 (25.1)   
8 weeks 15.2 (14.5) 20.5 (21.2)   
12 weeks 18.9 (19.7) 22.7 (22.9) 0.95 (-7.93 to 9.82) 0.832 
Stiffness severity later in the day 
(0-100mm)‡ 
    
Baseline 34.0 (27.0) 37.6 (25.4)   
4 weeks 17.8 (16.7) 25.4 (24.4)   
8 weeks 17.3 (17.1) 19.8 (20.1)   
12 weeks 18.1 (20.0) 15.8 (17.8) -2.99 (-10.53 to 4.59) 0.441 
SF-12 – physical (0-100 points)†     
Baseline 44.1 (10.7) 45.0 (9.7)   
12 weeks 47.1 (9.2) 46.7 (9.7) -0.98 (-3.81 to 1.86) 0.499 
SF-12 – mental (0-100 points)†     
Baseline 55.8 (8.1 ) 51.9 (9.0)   
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12 weeks 52.3 (9.6) 52.0 (9.6) -0.32 (-3.93 to 3.29) 0.862 
Total physical activity 
(hours/week) 
    
Baseline 17.5 (14.6) 15.4 (11.4)   
12 weeks 21.9 (16.7) 16.6 (12.1) -4.46 (-10.10 to 1.17) 0.120 
FHSQ=Foot Health Status Questionnaire; FFI=Foot Function Index; SF-12=Short Form 12 Health Survey 
* adjusted for baseline score and intervention group using analysis of covariance 
† higher scores indicate better function 
‡ higher scores indicate worse symptoms 
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Table 3. Adverse events reported during the study. Values are n (%). 
 
 Orthoses group (n=52) Footwear group (n=46) RR (95% CI) p 
Reported at least one adverse event 7 (15.6) 15 (38.5) 2.47 (1.12 to 5.44) 0.024* 
Blisters 2 (3.8) 3 (6.5) 1.34 (0.45 to 4.00) 0.442 
Discomfort 2 (3.8) 3 (6.5) 1.34 (0.45 to 4.00) 0.442 
Impaired balance 1 (1.9) 4 (8.7) 2.74 (0.47 to 15.98) 0.145 
Experienced a fall during trial 5 (11.1) 4 (10.3) 0.92 (0.27 to 3.20) 0.900 
Developed new back/lower limb pain during trial 31 (68.9) 28 (73.7) 1.07 (0.81 to 1.41) 0.629 
Low back 2 (3.8) 8 (17.4) 4.52 (1.01 to 20.22) 0.048* 
Hip 1 (1.9) 1 (2.2) 1.13 (0.07 to 17.57) 0.930 
Knee 4 (7.7) 3 (6.5) 0.85 (0.20 to 3.59) 0.823 
Lower leg 6 (11.5) 6 (13.0) 1.13 (0.39 to 3.26) 0.821 
Foot/ankle 22 (42.3) 20 (43.5) 1.03 (0.65 to 1.62) 0.907 
RR=relative risk 
* significantly higher risk in footwear group compared to orthoses group 
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FIGURE LEGENDS 
Figure 1. Prefabricated foot orthoses used in the trial. Top: plantar surface of left foot 
orthosis. Bottom: dorsal surface of right foot orthosis. Figure from Menz et al. (14). 
Figure 2. MBT

 Matwa footwear. Figure from Menz et al. (14). 
Figure 3. Flow of participants through study. 
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Figure 1. Prefabricated foot orthoses used in the trial. Top: plantar surface of left foot orthosis. Bottom: 
dorsal surface of right foot orthosis. Figure from Menz et al. (14).  
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Figure 2. MBT® Matwa footwear. Figure from Menz et al. (14).  
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Figure 3. Flow of participants through study.  
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